Dominika Grzybowska
Research Subjects
Dominika Grzybowska has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Kamil Idzik
Murcki Hospital in Katowice, Poland
20 shared publications - Michał Kurnik
Megrez Provincial Multi-Specialist Hospital in Tychy, Poland
20 shared publications - Weronika Grzyb-Kurnik
Megrez Provincial Multi-Specialist Hospital Limited Liability Company in Tychy, Poland
20 shared publications - Agnieszka Anna Gaczoł
Gabriel Narutowicz Municipal Specialist Hospital in Kraków, Poland
11 shared publications - Aleksander Urbaś
Murcki Hospital in Katowice, Poland
11 shared publications - Gabriela Piotrowska
Gabriel Narutowicz Municipal Specialist Hospital in Kraków, Poland
11 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73660
Obesity and depression - a bidirectional relationship and clinical implications
Background: Obesity has become a global civilization-related disease and constitutes an independent risk factor for numerous somatic disorders. Obesity can contribute to depression through low self-esteem, body image concerns, and stigmatization, while depression and chronic stress may promote obesity through emotional eating and binge eating. Both conditions share biological mechanisms, including HPA axis dysregulation, elevated cortisol levels, and chronic inflammation. Effective management requires an interdisciplinary approach that combines weight-loss interventions with psychological treatment. Weight reduction is associated with improved mood and quality of life. Aim: The aim of this narrative review is to analyze and synthesize the current state of knowledge regarding the relationship between obesity and depression. The paper seeks to identify the biological and psychological mechanisms linking both conditions, as well as to assess the impact of obesity on the risk of depression and, conversely, the impact of depressive disorders on the development and course of obesity. Material and methods: A literature review of scientific publications available in databases (including Google Scholar) was conducted, analyzing data on adolescents and adults with respect to pathophysiological and behavioral mechanisms. The review includes 24 articles published between 2006 and 2025. Results: Individuals with obesity have a 55% higher risk of developing depression, whereas patients with depression are 58% more likely to develop obesity. The prevalence of depression in the population of individuals with obesity is increased, and a modifying effect of sex is observed. Key mechanisms include dysregulation of the HPA axis, chronic inflammation, and disturbances in neurotransmission. Conclusions: Effective treatment requires an integrated approach combining weight reduction with psychological interventions. Treatment of obesity may lead to an improvement in mood.
- 29 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73660
Open AccessObesity and depression - a bidirectional relationship and clinical implications
Background: Obesity has become a global civilization-related disease and constitutes an independent risk factor for numerous somatic disorders. Obesity can contribute to depression through low self-esteem, body image concerns, and stigmatization, while depression and chronic stress may promote obesity through emotional eating and binge eating. Both conditions share biological mechanisms, including HPA axis dysregulation, elevated cortisol levels, and chronic inflammation. Effective management requires an interdisciplinary approach that combines weight-loss interventions with psychological treatment. Weight reduction is associated with improved mood and quality of life. Aim: The aim of this narrative review is to analyze and synthesize the current state of knowledge regarding the relationship between obesity and depression. The paper seeks to identify the biological and psychological mechanisms linking both conditions, as well as to assess the impact of obesity on the risk of depression and, conversely, the impact of depressive disorders on the development and course of obesity. Material and methods: A literature review of scientific publications available in databases (including Google Scholar) was conducted, analyzing data on adolescents and adults with respect to pathophysiological and behavioral mechanisms. The review includes 24 articles published between 2006 and 2025. Results: Individuals with obesity have a 55% higher risk of developing depression, whereas patients with depression are 58% more likely to develop obesity. The prevalence of depression in the population of individuals with obesity is increased, and a modifying effect of sex is observed. Key mechanisms include dysregulation of the HPA axis, chronic inflammation, and disturbances in neurotransmission. Conclusions: Effective treatment requires an integrated approach combining weight reduction with psychological interventions. Treatment of obesity may lead to an improvement in mood.
- Open Access
- 24 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73988
Nutritional Deficiencies as Modifiable Risk Factors for Postoperative Complications Following Abdominal Surgery
Postoperative complications after abdominal surgery are a major source of perioperative morbidity and mortality. Preoperative nutritional deficiencies, particularly hypoalbuminemia, vitamin D insufficiency, and iron deficiency anemia, are prevalent, underrecognized, modifiable risk factors impairing wound healing and immune defense, yet routine nutritional assessment remains inconsistent. This narrative review synthesizes evidence on the independent and cumulative impact of preoperative hypoalbuminemia, vitamin D insufficiency, and anemia on postoperative complications after abdominal surgery, and outlines strategies for nutritional optimization. A literature search was conducted in June 2026 using PubMed/MEDLINE, PubMed Central, and the Cochrane Library for English-language studies from January 2010 to June 2026, including randomized trials, cohort studies, systematic reviews, and meta-analyses reporting surgical outcomes in adults undergoing abdominal procedures. Hypoalbuminemia was the most robustly supported risk factor, with pooled data showing an odds ratio of 2.37 for surgical site infection. Vitamin D insufficiency was independently associated with increased infectious complications, and preoperative anemia contributed to tissue hypoxia, impaired collagen synthesis, and immune dysfunction. Co-occurring deficiencies were associated with cumulative impairment of immune and reparative function. Hypoalbuminemia, vitamin D insufficiency, and anemia are prevalent, mechanistically distinct, clinically significant modifiable risk factors for postoperative complications after abdominal surgery. Routine screening with validated tools and targeted laboratory evaluation is strongly supported by current evidence.
- 24 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73988
Open AccessNutritional Deficiencies as Modifiable Risk Factors for Postoperative Complications Following Abdominal Surgery
Postoperative complications after abdominal surgery are a major source of perioperative morbidity and mortality. Preoperative nutritional deficiencies, particularly hypoalbuminemia, vitamin D insufficiency, and iron deficiency anemia, are prevalent, underrecognized, modifiable risk factors impairing wound healing and immune defense, yet routine nutritional assessment remains inconsistent. This narrative review synthesizes evidence on the independent and cumulative impact of preoperative hypoalbuminemia, vitamin D insufficiency, and anemia on postoperative complications after abdominal surgery, and outlines strategies for nutritional optimization. A literature search was conducted in June 2026 using PubMed/MEDLINE, PubMed Central, and the Cochrane Library for English-language studies from January 2010 to June 2026, including randomized trials, cohort studies, systematic reviews, and meta-analyses reporting surgical outcomes in adults undergoing abdominal procedures. Hypoalbuminemia was the most robustly supported risk factor, with pooled data showing an odds ratio of 2.37 for surgical site infection. Vitamin D insufficiency was independently associated with increased infectious complications, and preoperative anemia contributed to tissue hypoxia, impaired collagen synthesis, and immune dysfunction. Co-occurring deficiencies were associated with cumulative impairment of immune and reparative function. Hypoalbuminemia, vitamin D insufficiency, and anemia are prevalent, mechanistically distinct, clinically significant modifiable risk factors for postoperative complications after abdominal surgery. Routine screening with validated tools and targeted laboratory evaluation is strongly supported by current evidence.
- Open Access
- 24 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 74100
Ageing with HIV Clinical and Organisational Challenges of Care
Combination antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) infection from a fatal disease into a manageable chronic condition; consequently, the population of people living with HIV (PLWH) is ageing rapidly. In many high-income settings more than half of PLWH are now aged 50 years or older. To characterise the clinical and organisational challenges that arise when HIV infection and biological ageing intersect, and to summarise the emerging models of integrated HIV-geriatric care intended to address them. A narrative review of English-language literature indexed in PubMed/MEDLINE was conducted, complemented by the current guidelines of the European AIDS Clinical Society (EACS) and the World Health Organization (WHO). Search terms combined the concepts of HIV, ageing, multimorbidity, frailty, polypharmacy, neurocognitive disorders, cardiovascular disease and models of care. Landmark studies, systematic reviews, meta-analyses and large cohort studies were prioritised. Chronic immune activation and inflammation ("inflammaging"), immunosenescence, and the cumulative effects of ART and traditional risk factors drive accelerated and accentuated biological ageing in PLWH. This manifests as premature multimorbidity, an increased burden of cardiovascular disease, metabolic and bone disorders, HIV-associated neurocognitive disorder (HAND), non-AIDS-defining cancers, frailty, and geriatric syndromes. Polypharmacy and drug-drug interactions further complicate management, and traditional HIV services are poorly configured for these needs. Caring for the ageing HIV population requires a paradigm shift towards integrated, multidisciplinary and geriatric-informed models of care, systematic screening for comorbidity and frailty, structured medication review, and adoption of frameworks such as the WHO Integrated Care for Older People (ICOPE) approach. These changes should be urgently implemented in national HIV care systems, including Poland’s.
- 24 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 74100
Open AccessAgeing with HIV Clinical and Organisational Challenges of Care
Combination antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) infection from a fatal disease into a manageable chronic condition; consequently, the population of people living with HIV (PLWH) is ageing rapidly. In many high-income settings more than half of PLWH are now aged 50 years or older. To characterise the clinical and organisational challenges that arise when HIV infection and biological ageing intersect, and to summarise the emerging models of integrated HIV-geriatric care intended to address them. A narrative review of English-language literature indexed in PubMed/MEDLINE was conducted, complemented by the current guidelines of the European AIDS Clinical Society (EACS) and the World Health Organization (WHO). Search terms combined the concepts of HIV, ageing, multimorbidity, frailty, polypharmacy, neurocognitive disorders, cardiovascular disease and models of care. Landmark studies, systematic reviews, meta-analyses and large cohort studies were prioritised. Chronic immune activation and inflammation ("inflammaging"), immunosenescence, and the cumulative effects of ART and traditional risk factors drive accelerated and accentuated biological ageing in PLWH. This manifests as premature multimorbidity, an increased burden of cardiovascular disease, metabolic and bone disorders, HIV-associated neurocognitive disorder (HAND), non-AIDS-defining cancers, frailty, and geriatric syndromes. Polypharmacy and drug-drug interactions further complicate management, and traditional HIV services are poorly configured for these needs. Caring for the ageing HIV population requires a paradigm shift towards integrated, multidisciplinary and geriatric-informed models of care, systematic screening for comorbidity and frailty, structured medication review, and adoption of frameworks such as the WHO Integrated Care for Older People (ICOPE) approach. These changes should be urgently implemented in national HIV care systems, including Poland’s.
- Open Access
- 14 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 74914
Ageing with HIV: Clinical and Organisational Challenges and the Role of Physical Activity in Healthy Ageing
Background. Combination antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition. Consequently, the population of people living with HIV (PLWH) is ageing rapidly, with over 50% aged 50 or older in many high-income settings. Objective. To characterise the clinical and organizational challenges at the intersection of HIV and biological ageing, highlight regular physical activity as a modifiable determinant of healthy ageing, and summarise emerging models of integrated HIV-geriatric care. Methods. A narrative review of English-language literature (PubMed/MEDLINE) and current EACS and WHO guidelines was conducted. Search terms covered HIV, ageing, multimorbidity, frailty, polypharmacy, neurocognitive disorders, cardiovascular disease, physical activity, and care models. Landmark studies, systematic reviews, and meta-analyses were prioritised. Results. Chronic inflammation ("inflammaging"), immunosenescence, ART toxicity, and traditional risk factors drive accelerated biological ageing in PLWH. This manifests as premature multimorbidity, increased cardiovascular, metabolic, and bone disease burden, HIV-associated neurocognitive disorder (HAND), non-AIDS cancers, and frailty. Polypharmacy complicates management, while traditional HIV services remain ill-equipped. Regular aerobic and resistance exercise represents a safe, cost-effective intervention that improves cardiorespiratory fitness, muscle strength, body composition, and physical function. Conclusions. Caring for ageing PLWH requires a shift toward integrated, multidisciplinary, geriatric-informed models. Essential elements include screening for comorbidities and frailty, medication reviews, physical activity promotion, and adopting frameworks like WHO ICOPE, which should be urgently implemented in national care systems, including Poland’s.
- 14 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 74914
Open AccessAgeing with HIV: Clinical and Organisational Challenges and the Role of Physical Activity in Healthy Ageing
Background. Combination antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition. Consequently, the population of people living with HIV (PLWH) is ageing rapidly, with over 50% aged 50 or older in many high-income settings. Objective. To characterise the clinical and organizational challenges at the intersection of HIV and biological ageing, highlight regular physical activity as a modifiable determinant of healthy ageing, and summarise emerging models of integrated HIV-geriatric care. Methods. A narrative review of English-language literature (PubMed/MEDLINE) and current EACS and WHO guidelines was conducted. Search terms covered HIV, ageing, multimorbidity, frailty, polypharmacy, neurocognitive disorders, cardiovascular disease, physical activity, and care models. Landmark studies, systematic reviews, and meta-analyses were prioritised. Results. Chronic inflammation ("inflammaging"), immunosenescence, ART toxicity, and traditional risk factors drive accelerated biological ageing in PLWH. This manifests as premature multimorbidity, increased cardiovascular, metabolic, and bone disease burden, HIV-associated neurocognitive disorder (HAND), non-AIDS cancers, and frailty. Polypharmacy complicates management, while traditional HIV services remain ill-equipped. Regular aerobic and resistance exercise represents a safe, cost-effective intervention that improves cardiorespiratory fitness, muscle strength, body composition, and physical function. Conclusions. Caring for ageing PLWH requires a shift toward integrated, multidisciplinary, geriatric-informed models. Essential elements include screening for comorbidities and frailty, medication reviews, physical activity promotion, and adopting frameworks like WHO ICOPE, which should be urgently implemented in national care systems, including Poland’s.
- Open Access
- 10 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 74783
Functional Dyspepsia in Clinical Practice Current Recommendations and Future Perspectives
Background:Functional dyspepsia (FD) is a common disorder of gut–brain interaction and a major cause of chronic upper gastrointestinal symptoms and impaired quality of life. Current evidence challenges the traditional view of FD as solely a gastric motility disorder and indicates a multifactorial pathophysiology involving motor dysfunction, visceral hypersensitivity, duodenal immune activation, epithelial barrier impairment, gut microbiota alterations, and dysregulated gut–brain communication. Aim:To review current knowledge of the pathophysiology, clinical presentation, diagnosis, and evidence-based management of FD, with emphasis on emerging therapeutic targets and precision medicine. Material and methods:A narrative review was conducted using international clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and translational studies concerning FD diagnosis, treatment, and recent advances in disease mechanisms. Results:FD is a heterogeneous disorder in which several overlapping biological mechanisms contribute to symptom generation. Diagnosis is primarily based on the Rome IV criteria after exclusion of structural disease. Established management includes lifestyle modification, Helicobacter pylori eradication, proton pump inhibitors, prokinetics, neuromodulators, and psychological therapies. Emerging approaches targeting the duodenal microenvironment, epithelial barrier, gut microbiota, and gut–brain axis are promising. Nevertheless, treatment efficacy remains modest because of biological heterogeneity and the lack of validated biomarkers for patient stratification. Conclusions:The evolving understanding of FD supports a shift from empirical symptom-based treatment toward individualized, mechanism-informed care. Future research should focus on clinically applicable biomarkers, improved phenotyping, and high-quality clinical trials to enable precision medicine and improve long-term outcomes.
- 10 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 74783
Open AccessFunctional Dyspepsia in Clinical Practice Current Recommendations and Future Perspectives
Background:Functional dyspepsia (FD) is a common disorder of gut–brain interaction and a major cause of chronic upper gastrointestinal symptoms and impaired quality of life. Current evidence challenges the traditional view of FD as solely a gastric motility disorder and indicates a multifactorial pathophysiology involving motor dysfunction, visceral hypersensitivity, duodenal immune activation, epithelial barrier impairment, gut microbiota alterations, and dysregulated gut–brain communication. Aim:To review current knowledge of the pathophysiology, clinical presentation, diagnosis, and evidence-based management of FD, with emphasis on emerging therapeutic targets and precision medicine. Material and methods:A narrative review was conducted using international clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and translational studies concerning FD diagnosis, treatment, and recent advances in disease mechanisms. Results:FD is a heterogeneous disorder in which several overlapping biological mechanisms contribute to symptom generation. Diagnosis is primarily based on the Rome IV criteria after exclusion of structural disease. Established management includes lifestyle modification, Helicobacter pylori eradication, proton pump inhibitors, prokinetics, neuromodulators, and psychological therapies. Emerging approaches targeting the duodenal microenvironment, epithelial barrier, gut microbiota, and gut–brain axis are promising. Nevertheless, treatment efficacy remains modest because of biological heterogeneity and the lack of validated biomarkers for patient stratification. Conclusions:The evolving understanding of FD supports a shift from empirical symptom-based treatment toward individualized, mechanism-informed care. Future research should focus on clinically applicable biomarkers, improved phenotyping, and high-quality clinical trials to enable precision medicine and improve long-term outcomes.
- Open Access
- 6 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 74784
Sexual Dysfunction Associated with Selective Serotonin Reuptake Inhibitors: Mechanisms, Clinical Manifestations, Management Strategies, and Post-SSRI Sexual Dysfunction - A Narrative Review
Background: Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder and anxiety disorders. Sexual dysfunction is among their most common adverse effects, impairing quality of life and treatment adherence. Increasing attention has focused on post-SSRI sexual dysfunction (PSSD), in which symptoms persist after antidepressant discontinuation. Objective: To summarize current evidence on sexual physiology, mechanisms and clinical features of antidepressant-induced sexual dysfunction (AISD) and PSSD, and available management strategies. Methods: A narrative review of English-language literature published between 2020 and 2026 was conducted using PubMed and Google Scholar. Original studies, systematic reviews, meta-analyses, randomized trials, observational studies, and relevant case reports were included, along with essential earlier landmark publications. Results: SSRI-associated sexual dysfunction may affect desire, arousal, erection, ejaculation, orgasm, and sexual satisfaction. Prevalence estimates vary because of differences in study populations and assessment methods. Symptoms usually improve after dose reduction or discontinuation, but may persist as PSSD. Proposed mechanisms include serotonergic dysregulation, altered dopaminergic and neuroendocrine signaling, epigenetic changes, TRP ion channel dysfunction, neurotoxicity, and gut–brain axis disturbances, although none has been confirmed. Management includes dose reduction, switching to antidepressants with a lower risk of sexual adverse effects, pharmacological augmentation, and selected non-pharmacological interventions. No evidence-based treatment for PSSD has been established. Conclusions: Sexual dysfunction is a major adverse effect of SSRI therapy. Routine assessment before and during treatment may facilitate recognition and management. High-quality prospective studies are needed to clarify the epidemiology, mechanisms, and optimal treatment of PSSD.
- 6 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 74784
Open AccessSexual Dysfunction Associated with Selective Serotonin Reuptake Inhibitors: Mechanisms, Clinical Manifestations, Management Strategies, and Post-SSRI Sexual Dysfunction - A Narrative Review
Background: Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder and anxiety disorders. Sexual dysfunction is among their most common adverse effects, impairing quality of life and treatment adherence. Increasing attention has focused on post-SSRI sexual dysfunction (PSSD), in which symptoms persist after antidepressant discontinuation. Objective: To summarize current evidence on sexual physiology, mechanisms and clinical features of antidepressant-induced sexual dysfunction (AISD) and PSSD, and available management strategies. Methods: A narrative review of English-language literature published between 2020 and 2026 was conducted using PubMed and Google Scholar. Original studies, systematic reviews, meta-analyses, randomized trials, observational studies, and relevant case reports were included, along with essential earlier landmark publications. Results: SSRI-associated sexual dysfunction may affect desire, arousal, erection, ejaculation, orgasm, and sexual satisfaction. Prevalence estimates vary because of differences in study populations and assessment methods. Symptoms usually improve after dose reduction or discontinuation, but may persist as PSSD. Proposed mechanisms include serotonergic dysregulation, altered dopaminergic and neuroendocrine signaling, epigenetic changes, TRP ion channel dysfunction, neurotoxicity, and gut–brain axis disturbances, although none has been confirmed. Management includes dose reduction, switching to antidepressants with a lower risk of sexual adverse effects, pharmacological augmentation, and selected non-pharmacological interventions. No evidence-based treatment for PSSD has been established. Conclusions: Sexual dysfunction is a major adverse effect of SSRI therapy. Routine assessment before and during treatment may facilitate recognition and management. High-quality prospective studies are needed to clarify the epidemiology, mechanisms, and optimal treatment of PSSD.
- Open Access
- 31 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 73983
Safety of the Use of Psychiatric Medications in Pregnant Patients. A Review of Current Medical Knowledge
Pregnancy is a period of increased vulnerability to mental disorders and therapeutic challenges. Depression affects 10-15% of pregnant women, anxiety disorders up to 20%, and bipolar disorder 1-2% of women of reproductive age. Discontinuation of mood stabilizers is associated with up to a twofold increase in the risk of relapse. Untreated disorders increase the risk of obstetric and neonatal complications as well as suicide. This paper is a narrative review of the literature from 2020-2025 (PubMed/MEDLINE, Embase, PsycINFO) concerning the safety of psychiatric medications during pregnancy. SSRIs, SNRIs, TCAs, antipsychotics, mood stabilizers, and benzodiazepines were discussed, taking into account the risk of congenital malformations, neonatal outcomes, and child development. Among the agents considered relatively safe were sertraline, haloperidol, quetiapine, and lamotrigine; valproate and paroxetine are contraindicated; data for some drugs remain limited. The importance of an individualized risk--benefit analysis, use of the lowest effective dose, avoidance of polytherapy, and planning of perinatal care was emphasized. ECT was indicated as an alternative option. Discontinuation of treatment in severe disorders is not recommended.
- 31 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 73983
Open AccessSafety of the Use of Psychiatric Medications in Pregnant Patients. A Review of Current Medical Knowledge
Pregnancy is a period of increased vulnerability to mental disorders and therapeutic challenges. Depression affects 10-15% of pregnant women, anxiety disorders up to 20%, and bipolar disorder 1-2% of women of reproductive age. Discontinuation of mood stabilizers is associated with up to a twofold increase in the risk of relapse. Untreated disorders increase the risk of obstetric and neonatal complications as well as suicide. This paper is a narrative review of the literature from 2020-2025 (PubMed/MEDLINE, Embase, PsycINFO) concerning the safety of psychiatric medications during pregnancy. SSRIs, SNRIs, TCAs, antipsychotics, mood stabilizers, and benzodiazepines were discussed, taking into account the risk of congenital malformations, neonatal outcomes, and child development. Among the agents considered relatively safe were sertraline, haloperidol, quetiapine, and lamotrigine; valproate and paroxetine are contraindicated; data for some drugs remain limited. The importance of an individualized risk--benefit analysis, use of the lowest effective dose, avoidance of polytherapy, and planning of perinatal care was emphasized. ECT was indicated as an alternative option. Discontinuation of treatment in severe disorders is not recommended.
- Open Access
- 31 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73641
Emerging Biologic Strategies in Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease, which substantially impairs patients’ quality of life. Despite ongoing advances, effective long-term management remains challenging in many cases. Conventional therapies are often associated with significant adverse effects and limited suitability for sustained use. This review provides an overview of the current landscape of novel biological therapeutics and their molecular targets. Several biologic therapies are already well established in clinical practice. Among them, IL-23 inhibitors stand out due to their high efficacy in both inducing and maintaining remission. Agents targeting the TL1A pathway, as well as human amniotic epithelial cells have shown promising early results and are currently under further investigation in clinical trials. Nevertheless, discontinuation of some biologics trials proves that not all theoretically attractive targets translate into meaningful clinical outcomes. Importantly, variability in efficacy can be observed even within the same class of drugs. This is exemplified by the success of upadacitinib in contrast to tofacitinib, which did not meet primary endpoints and was not further developed for this indication. Overall, these findings highlight both the progress achieved and the ongoing challenges in optimizing targeted therapies for Crohn’s disease.
- 31 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73641
Open AccessEmerging Biologic Strategies in Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease, which substantially impairs patients’ quality of life. Despite ongoing advances, effective long-term management remains challenging in many cases. Conventional therapies are often associated with significant adverse effects and limited suitability for sustained use. This review provides an overview of the current landscape of novel biological therapeutics and their molecular targets. Several biologic therapies are already well established in clinical practice. Among them, IL-23 inhibitors stand out due to their high efficacy in both inducing and maintaining remission. Agents targeting the TL1A pathway, as well as human amniotic epithelial cells have shown promising early results and are currently under further investigation in clinical trials. Nevertheless, discontinuation of some biologics trials proves that not all theoretically attractive targets translate into meaningful clinical outcomes. Importantly, variability in efficacy can be observed even within the same class of drugs. This is exemplified by the success of upadacitinib in contrast to tofacitinib, which did not meet primary endpoints and was not further developed for this indication. Overall, these findings highlight both the progress achieved and the ongoing challenges in optimizing targeted therapies for Crohn’s disease.
- Open Access
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 73985
Targeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review
Background: Psoriatic arthritis (PsA) and juvenile psoriatic arthritis (JPsA) are chronic inflammatory diseases with heterogeneous, multi-domain presentation; targeted therapies against TNF-alpha, IL-17 and the JAK-STAT pathway have expanded treatment options.Aim: To evaluate efficacy and safety of three classes of targeted therapies in PsA and JPsA: TNF-alpha inhibitors (TNF-i), IL-17 inhibitors (IL-17-i) and Janus kinase inhibitors (JAK-i).Material and methods: A narrative PubMed (MEDLINE) review of phase I-III randomized trials and open-label extensions, real-world studies, and selected reviews assessing efficacy and safety of TNF-i, IL-17-i and JAK-i in adults and children with PsA/JPsA.Results: Anti-TNF therapies show high ACR response rates, favourable skin effects, and inhibition of radiographic progression, with acceptable long-term safety. IL-17-i provide sustained improvement across major PsA domains, particularly in TNF-i-naive patients, with a stable safety profile. JAK-i are effective after failure of conventional and biologic treatment, improving joint activity, function and quality of life, but carry a characteristic adverse-event profile requiring assessment. Real-world analyses in PsA and axial spondyloarthritis show no significantly increased cardiovascular or malignancy risk with JAK-i versus anti-TNF/anti-IL-17 therapies, though rheumatoid arthritis data warrant caution in high-risk patients. In JPsA, TNF-i remain the principal biologic class, while anti-IL-17 trials confirm efficacy and safety in children.Conclusions: Targeted therapy of PsA and JPsA requires individualization based on phenotype, prior treatment, and cardiovascular, thromboembolic and oncologic risk. Further paediatric studies are needed to define each class's role in JPsA management.
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 73985
Open AccessTargeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review
Background: Psoriatic arthritis (PsA) and juvenile psoriatic arthritis (JPsA) are chronic inflammatory diseases with heterogeneous, multi-domain presentation; targeted therapies against TNF-alpha, IL-17 and the JAK-STAT pathway have expanded treatment options.Aim: To evaluate efficacy and safety of three classes of targeted therapies in PsA and JPsA: TNF-alpha inhibitors (TNF-i), IL-17 inhibitors (IL-17-i) and Janus kinase inhibitors (JAK-i).Material and methods: A narrative PubMed (MEDLINE) review of phase I-III randomized trials and open-label extensions, real-world studies, and selected reviews assessing efficacy and safety of TNF-i, IL-17-i and JAK-i in adults and children with PsA/JPsA.Results: Anti-TNF therapies show high ACR response rates, favourable skin effects, and inhibition of radiographic progression, with acceptable long-term safety. IL-17-i provide sustained improvement across major PsA domains, particularly in TNF-i-naive patients, with a stable safety profile. JAK-i are effective after failure of conventional and biologic treatment, improving joint activity, function and quality of life, but carry a characteristic adverse-event profile requiring assessment. Real-world analyses in PsA and axial spondyloarthritis show no significantly increased cardiovascular or malignancy risk with JAK-i versus anti-TNF/anti-IL-17 therapies, though rheumatoid arthritis data warrant caution in high-risk patients. In JPsA, TNF-i remain the principal biologic class, while anti-IL-17 trials confirm efficacy and safety in children.Conclusions: Targeted therapy of PsA and JPsA requires individualization based on phenotype, prior treatment, and cardiovascular, thromboembolic and oncologic risk. Further paediatric studies are needed to define each class's role in JPsA management.
- Open Access
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 74008
Caffeine Tolerance in Endurance Sports: Does Habitual Intake Reduce the Effectiveness of Acute Supplementation?
Background: Caffeine is a well-established ergogenic aid that improves endurance performance at acute doses of 3–6 mg/kg. Widespread habitual intake, mainly via coffee, raises the question whether chronic exposure blunts this effect. Aim: To critically assess whether regular caffeine consumption, particularly habitual coffee intake, modifies the acute ergogenic response to pre-exercise caffeine in endurance contexts. Methods: A structured, non-exhaustive search (January 2020–June 2026) was performed in PubMed/MEDLINE, PubMed Central, Scopus, Web of Science, and the Cochrane Library, with citation tracking. Priority was given to systematic reviews, meta-analyses, randomized placebo-controlled crossover trials, and prospective studies on endurance performance, habitual intake, and acute responses; mechanistic papers were included selectively. Results: Acute caffeine consistently enhances endurance performance. The largest meta-analysis indicates no significant attenuation of the pooled ergogenic effect with habitual intake. However, longitudinal data suggest that repeated daily exposure may reduce the magnitude of benefit over time without abolishing it, consistent with partial, context-dependent habituation. Inter-individual variability is influenced by dose, timing, delivery form, and training status; genetic effects remain insufficiently defined for clinical personalization. Conclusions: Habitual caffeine use does not eliminate the ergogenic effect of acute supplementation in most endurance settings, but may attenuate responsiveness in some individuals. Evidence supports individualized strategies based on habitual intake, prior response, timing, and tolerability rather than routine abstinence or dose escalation. Well-controlled longitudinal studies are needed to clarify the extent and mechanisms of habituation.
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 74008
Open AccessCaffeine Tolerance in Endurance Sports: Does Habitual Intake Reduce the Effectiveness of Acute Supplementation?
Background: Caffeine is a well-established ergogenic aid that improves endurance performance at acute doses of 3–6 mg/kg. Widespread habitual intake, mainly via coffee, raises the question whether chronic exposure blunts this effect. Aim: To critically assess whether regular caffeine consumption, particularly habitual coffee intake, modifies the acute ergogenic response to pre-exercise caffeine in endurance contexts. Methods: A structured, non-exhaustive search (January 2020–June 2026) was performed in PubMed/MEDLINE, PubMed Central, Scopus, Web of Science, and the Cochrane Library, with citation tracking. Priority was given to systematic reviews, meta-analyses, randomized placebo-controlled crossover trials, and prospective studies on endurance performance, habitual intake, and acute responses; mechanistic papers were included selectively. Results: Acute caffeine consistently enhances endurance performance. The largest meta-analysis indicates no significant attenuation of the pooled ergogenic effect with habitual intake. However, longitudinal data suggest that repeated daily exposure may reduce the magnitude of benefit over time without abolishing it, consistent with partial, context-dependent habituation. Inter-individual variability is influenced by dose, timing, delivery form, and training status; genetic effects remain insufficiently defined for clinical personalization. Conclusions: Habitual caffeine use does not eliminate the ergogenic effect of acute supplementation in most endurance settings, but may attenuate responsiveness in some individuals. Evidence supports individualized strategies based on habitual intake, prior response, timing, and tolerability rather than routine abstinence or dose escalation. Well-controlled longitudinal studies are needed to clarify the extent and mechanisms of habituation.